Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GALTNASDAQ:IPANASDAQ:JMACNASDAQ:JSPR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGALTGalectin Therapeutics$1.41-10.5%$1.45$0.73▼$3.41$88.77M0.62317,310 shs132,799 shsIPAImmunoPrecise Antibodies$0.46-2.6%$0.42$0.27▼$1.36$20.82M-0.052.11 million shs213,998 shsJMACMaxpro Capital Acquisition$5.81-4.6%$6.80$7.50▼$19.22$78.02M0.0174,040 shs951 shsJSPRJasper Therapeutics$4.40+1.9%$4.68$3.13▼$26.84$66.10M2.74289,474 shs167,394 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGALTGalectin Therapeutics-10.51%+8.08%+10.63%+7.25%-56.64%IPAImmunoPrecise Antibodies-1.30%-1.60%+18.18%-8.23%-64.17%JMACMaxpro Capital Acquisition-4.60%-11.84%-3.17%-30.00%+1,343.48%JSPRJasper Therapeutics+2.44%-18.22%+26.80%-28.34%-79.24%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGALTGalectin Therapeutics0.7079 of 5 stars3.00.00.00.00.01.70.0IPAImmunoPrecise Antibodies1.9774 of 5 stars3.54.00.00.00.00.01.3JMACMaxpro Capital AcquisitionN/AN/AN/AN/AN/AN/AN/AN/AJSPRJasper Therapeutics2.3176 of 5 stars3.52.00.00.02.81.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGALTGalectin Therapeutics 2.00Hold$11.00682.92% UpsideIPAImmunoPrecise Antibodies 3.00Buy$4.00779.12% UpsideJMACMaxpro Capital Acquisition 0.00N/AN/AN/AJSPRJasper Therapeutics 3.00Buy$62.501,320.45% UpsideCurrent Analyst Ratings BreakdownLatest IPA, JMAC, GALT, and JSPR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/11/2025IPAImmunoPrecise AntibodiesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.004/2/2025GALTGalectin TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral4/1/2025IPAImmunoPrecise AntibodiesBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSpeculative Buy ➝ Speculative Buy$3.00 ➝ $3.003/31/2025IPAImmunoPrecise AntibodiesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$7.00 ➝ $5.003/14/2025IPAImmunoPrecise AntibodiesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.003/11/2025JSPRJasper TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.00 ➝ $40.002/13/2025JSPRJasper TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$38.00(Data available from 5/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGALTGalectin TherapeuticsN/AN/AN/AN/A($1.01) per shareN/AIPAImmunoPrecise Antibodies$24.00M0.87N/AN/A$0.93 per share0.49JMACMaxpro Capital AcquisitionN/AN/AN/AN/AN/AN/AJSPRJasper TherapeuticsN/AN/AN/AN/A$7.03 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGALTGalectin Therapeutics-$41.07M-$0.76N/AN/AN/AN/AN/A-163.15%5/21/2025 (Estimated)IPAImmunoPrecise Antibodies-$20.13M-$1.16N/AN/AN/A-114.50%-73.74%-42.68%N/AJMACMaxpro Capital AcquisitionN/AN/A0.00∞N/AN/AN/AN/AN/AJSPRJasper Therapeutics-$64.46M-$4.86N/AN/AN/AN/A-67.64%-58.53%5/13/2025 (Estimated)Latest IPA, JMAC, GALT, and JSPR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2025Q1 2025GALTGalectin Therapeutics-$0.20N/AN/AN/AN/AN/A5/13/2025Q1 2025JSPRJasper Therapeutics-$1.17N/AN/AN/AN/AN/A3/31/2025Q4 2024GALTGalectin Therapeutics-$0.16-$0.19-$0.03-$0.19N/AN/A3/28/2025Q3 2025IPAImmunoPrecise Antibodies-$0.06-$0.06N/A-$0.46$6.59 million$4.23 million2/27/2025Q4 2024JSPRJasper Therapeutics-$1.27-$1.62-$0.35-$1.62N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGALTGalectin TherapeuticsN/AN/AN/AN/AN/AIPAImmunoPrecise AntibodiesN/AN/AN/AN/AN/AJMACMaxpro Capital AcquisitionN/AN/AN/AN/AN/AJSPRJasper TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGALTGalectin TherapeuticsN/A1.131.13IPAImmunoPrecise Antibodies0.361.010.85JMACMaxpro Capital AcquisitionN/AN/AN/AJSPRJasper TherapeuticsN/A7.617.61Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGALTGalectin Therapeutics11.68%IPAImmunoPrecise Antibodies6.70%JMACMaxpro Capital Acquisition73.18%JSPRJasper Therapeutics79.85%Insider OwnershipCompanyInsider OwnershipGALTGalectin Therapeutics50.10%IPAImmunoPrecise Antibodies6.83%JMACMaxpro Capital Acquisition19.27%JSPRJasper Therapeutics2.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGALTGalectin Therapeutics963.18 million31.32 millionOptionableIPAImmunoPrecise Antibodies8045.77 million28.94 millionNot OptionableJMACMaxpro Capital Acquisition2,02113.43 million10.84 millionNot OptionableJSPRJasper Therapeutics2015.02 million14.60 millionOptionableIPA, JMAC, GALT, and JSPR HeadlinesRecent News About These CompaniesJasper Therapeutics (JSPR) Expected to Announce Earnings on TuesdayMay 8 at 11:21 AM | marketbeat.comJasper Therapeutics, Inc. (NASDAQ:JSPR) Shares Acquired by Braidwell LPMay 8 at 6:30 AM | marketbeat.comJasper Therapeutics, Inc. (NASDAQ:JSPR) Receives Consensus Recommendation of "Buy" from AnalystsMay 8 at 4:23 AM | marketbeat.comWhy Jasper Therapeutics, Inc.’s (JSPR) Stock Is Down 5.34%May 6 at 10:42 PM | aaii.comAlly Bridge Group NY LLC Decreases Stock Holdings in Jasper Therapeutics, Inc. (NASDAQ:JSPR)May 4, 2025 | marketbeat.comBoxer Capital Management LLC Buys New Shares in Jasper Therapeutics, Inc. (NASDAQ:JSPR)May 4, 2025 | marketbeat.comT. Rowe Price Investment Management Inc. Makes New $1.76 Million Investment in Jasper Therapeutics, Inc. (NASDAQ:JSPR)April 30, 2025 | marketbeat.comWhy Jasper Therapeutics, Inc.’s (JSPR) Stock Is Up 7.05%April 22, 2025 | aaii.comJasper Therapeutics, Inc. (NASDAQ:JSPR) Receives Average Rating of "Buy" from AnalystsApril 13, 2025 | marketbeat.comWhy Jasper Therapeutics, Inc.’s (JSPR) Stock Is Up 7.55%April 11, 2025 | aaii.comJasper Therapeutics inks new sales agreement, ends previous dealMarch 21, 2025 | uk.investing.comJasper Therapeutics files $300M mixed securities shelfMarch 19, 2025 | markets.businessinsider.comJasper Therapeutics presents updated data from Phase 1b/2a BEACON studyMarch 2, 2025 | msn.comJasper Therapeutics Presents Clinical and Preclinical Briquilimab Data at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual MeetingMarch 1, 2025 | globenewswire.comJasper Therapeutics Announces Late-Breaking Briquilimab Presentation at the American Academy of Dermatology (AAD) Annual MeetingFebruary 28, 2025 | globenewswire.comJasper Therapeutics Reports Promising Clinical ProgressFebruary 28, 2025 | tipranks.comJasper Therapeutics reports Q4 EPS ($1.62), consensus ($1.23)February 27, 2025 | markets.businessinsider.comJasper Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Corporate UpdateFebruary 27, 2025 | globenewswire.comJasper Therapeutics to Present at Upcoming March Investor ConferencesFebruary 25, 2025 | globenewswire.comUBS Initiates Coverage of Jasper Therapeutics (JSPR) with Buy RecommendationFebruary 14, 2025 | msn.comJasper Therapeutics initiated with a Buy at UBSFebruary 13, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAre Tariffs Threatening Disney’s Comeback Story?By Jea Yu | April 9, 2025View Are Tariffs Threatening Disney’s Comeback Story?Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Market Anticipation Builds: Joby Stock Climbs Ahead of EarningsBy Jeffrey Neal Johnson | April 25, 2025View Market Anticipation Builds: Joby Stock Climbs Ahead of EarningsTake-Two Interactive: A Defensive Play Set to ExplodeBy Jeffrey Neal Johnson | April 22, 2025View Take-Two Interactive: A Defensive Play Set to ExplodeInstitutions Skipped the Rally: Where the Money WentBy Gabriel Osorio-Mazilli | May 8, 2025View Institutions Skipped the Rally: Where the Money WentIPA, JMAC, GALT, and JSPR Company DescriptionsGalectin Therapeutics NASDAQ:GALT$1.40 -0.17 (-10.51%) Closing price 05/8/2025 03:59 PM EasternExtended Trading$1.38 -0.03 (-1.78%) As of 05/8/2025 06:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.ImmunoPrecise Antibodies NASDAQ:IPA$0.46 -0.01 (-2.57%) Closing price 05/8/2025 03:58 PM EasternExtended Trading$0.46 +0.00 (+0.66%) As of 05/8/2025 06:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; and peptide production for subsequent antibody discovery campaign. In addition, it provides B cell select platform which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and select the desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection. The company also offers phage display, a custom immune libraries from multiple species; and CAR development, an adaptable antibody which allows the inclusion of functional data early in the screening funnel. Further, it provides silico developability, a profiling toolset for antibody lead candidates; and vitro analytical tools for the study of various critical quality attributes. Additionally, the company offers LucinaTech, an antibody humanization to identify essential framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; and antibody chimerization for cloning and production of variable antibody domain. It also provides Eurofins preclinical services; hybrid service model, a service model designed to reduce time and risk with custom technologies and applications; and breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts. The company was incorporated in 1983 and is headquartered in Victoria, Canada.Maxpro Capital Acquisition NASDAQ:JMAC$5.81 -0.28 (-4.60%) As of 05/7/2025Maxpro Capital Acquisition Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2021 and is based in Taipei City, Taiwan.Jasper Therapeutics NASDAQ:JSPR$4.40 +0.08 (+1.85%) Closing price 05/8/2025 03:59 PM EasternExtended Trading$4.43 +0.03 (+0.68%) As of 05/8/2025 06:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Is Energy Transfer Undervalued or a Value Trap? Carvana’s Stock Price Rebound Shifts Into a Higher Gear Why Investors Should Be Careful About AMC's Bitcoin Dreams Alphabet Slumps as Apple Eyes AI Search—Is the Sell-Off Overdone? Joby's Q1: Key Milestones Achieved as Path to Market Crystalizes Rockwell Automation: Tailwinds From Onshoring U.S. Production IBM's AI Offensive: Assessing IBM's Path to Renewed Growth Upwork's Earnings Beat Fuels Stock Rally—Is Freelancing Booming? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
